Toll-Like Receptor Signaling and Liver Fibrosis
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Liver fibrosis occurs as a wound-healing scar response following acute and chronic liver inflammation including alcoholic liver disease, non-alcoholic steatohepatitis, hepatitis B and C, and autoimmune hepatitis. Myofibroblasts, mainly transdifferentiated from hepatic stellate cells, are pivotal cell types that produce fibrillar collagen. The activation of inflammatory cells, including Kupffer cells, is a crucial step for activating hepatic stellate cells. Toll-like receptors (TLRs) are pattern recognition receptors that sense pathogen-associated molecular patterns (PAMPs), which discriminate the products of microorganisms from the host. TLRs are expressed on Kupffer cells, endothelial cells, dendritic cells, biliary epithelial cells, hepatic stellate cells, and hepatocytes in the liver. TLR signaling induces potent innate immune responses in these cell types. The liver is constantly exposed to PAMPs, such as LPS and bacterial DNA through bacterial translocation because there is a unique anatomical link, the portal vein system between liver and intestine. Recent evidence demonstrates the role of TLRs in the activation of hepatic immune cells and stellate cells during liver fibrosis. Moreover, crosstalk between TLR4 signaling and TGF-βsignaling in hepatic stellate cells has been reported. This paper highlights the role of TLR signaling in stellate cell activation and the progression of liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251 · cited 1×
“Mice were orally treated with a cocktail of nonabsorbable broad-spectrum antibiotics (ampicillin, neomycin, metronidazole, and vancomycin) for 4 weeks prior to induction of liver fibrosis [10, 21].”
MethodCirculating mitochondrial DAMPs cause inflammatory responses to injury
Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., Brohi, K., Itagaki, K., & Hauser, C. J. (2010) · Nature · doi:10.1038/nature08780 · Cited by 3,812 · cited 1×
“Very recently, mitochondrial DNA has been reported as an endogenous TLR9 ligand [49], which might be an endogenous ligand to activate HSCs.”
BackgroundToll-like receptors in innate immunity
Takeda, K. (2004) · International Immunology · doi:10.1093/intimm/dxh186 · Cited by 3,328 · cited 16×
“CpGDNA-primed fibrotic liver CD11c-positive cells increased NK cell cytotoxicity and cytokine production, including IFN-γ in a TNF-α dependent manner [41].”
BackgroundInfluentialTLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Self-citationCrispe, I. N. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132629 · Cited by 986 · cited 2×
“A unique anatomical link, the portal vein system between the liver and intestines, may allow for the exposure of bacterial products, including LPS and bacterial DNA, to the liver [11].”
BackgroundToll‐like receptors and adaptor molecules in liver disease: Update†
Seki, E., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.22306 · Cited by 722 · cited 2×
“Kupffer cells are well-known targets for TLR4 ligand LPS and produce various types of inflammatory and fibrogenic cytokines, which may activate HSCs [6, 7].”
BackgroundSelf-citationChang, L., Kamata, H., Solinas, G., Luo, J.-L., Maeda, S., Venuprasad, K., Liu, Y.-C., & Karin, M. (2006) · Cell · doi:10.1016/j.cell.2006.01.021 · Cited by 706 · cited 1×
“Prolonged JNK activation induces phosphorylation of the E3 ligase Itch and subsequent ubiquitination and degradation of caspase-8 inhibitor c-FLIP, which accelerates hepatocyte apoptosis [46].”
BackgroundHepatic T cells and liver tolerance
Crispe, I. N. (2003) · Nature Reviews Immunology · doi:10.1038/nri981 · Cited by 661 · cited 1×
“However, the hepatic immune response is strictly regulated to avoid a harmful response in physiological conditions [11, 12].”
BackgroundRadaeva, S., Sun, R., Jaruga, B., Nguyen, V. T., Tian, Z., & Gao, B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.055 · Cited by 610 · cited 6×
“TLR3 ligand poly I:C treatment attenuates liver fibrosis induced by the treatment of 3,5-diethoxycarbonyl-1,4-dehydrocollidine (DDC) diet and CCl4 [36].”
InfluentialLin, R.-S., Lee, F.-Y., Lee, S.-D., Tsai, Y.-T., Lin, H. C., Rei-Hwa, L., Wan-Ching, H., Cheng-Chun, H., Sun-Sang, W., & Kwang-Juei, L. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80424-2 · Cited by 355 · cited 1×
“Lipopolysaccharide (LPS, also known as endotoxin) levels in systemic and portal vein blood are increased in patients with cirrhosis [3, 4].”
BackgroundApoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9
Watanabe, A., Hashmi, A., Gomes, D. A., Town, T., Badou, A., Flavell, R. A., & Mehal, W. Z. (2007) · Hepatology · doi:10.1002/hep.21867 · Cited by 262
Guo, J., Loke, J., Zheng, F., Hong, F., Yea, S., Fukata, M., Tarocchi, M., Abar, O. T., Huang, H., Sninsky, J. J., et al. (2009) · Hepatology · doi:10.1002/hep.22697 · Cited by 217
LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice
Isayama, F., Hines, I. N., Kremer, M., Milton, R. J., Byrd, C. L., Perry, A. W., McKim, S. E., Parsons, C., Rippe, R. A., & Wheeler, M. D. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00405.2005 · Cited by 123
Cited by
Microbiota, cirrhosis, and the emerging oral-gut-liver axis
Acharya, C., Sahingur, S. E., & Bajaj, J. S. (2017) · JCI Insight · doi:10.1172/jci.insight.94416 · Cited by 256
Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro
Leite, S. B., Roosens, T., El Taghdouini, A., Mannaerts, I., Smout, A. J., Najimi, M., Sokal, E., Noor, F., Chesne, C., & van Grunsven, L. A. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.026 · Cited by 234
Role of cAMP and phosphodiesterase signaling in liver health and disease
Wahlang, B., McClain, C., Barve, S., & Gobejishvili, L. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.06.005 · Cited by 168
Vila, I. K., Badin, P.-M., Marques, M.-A., Monbrun, L., Lefort, C., Mir, L., Louche, K., Bourlier, V., Roussel, B., Gui, P., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.062 · Cited by 165
Furusho, H., Miyauchi, M., Hyogo, H., Inubushi, T., Ao, M., Ouhara, K., Hisatune, J., Kurihara, H., Sugai, M., Hayes, C. N., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-012-0738-1 · Cited by 157
“Recently, accumulating data have demonstrated that gut-derived LPS can act as a second hit and results in progressive liver injury leading to NASH [24, 25].”
Background
Metadata
- Authors
- Aoyama, T., Paik, Y.-H., & Seki, E.
- Venue
- Gastroenterology Research and Practice
- Publisher
- Wiley
- Published
- 2010
- Volume
- 2010
- Pages
- 1-8
- ISSN
- 1687-6121 (ISSN-L)
- 1687-630X
- OpenAlex
- W2162615652
- Cited by
- 137
- References
- 14
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.